| Author | Year | Ref | Host animal | Donor animal | Cell type | Target tissue | Injection site | Injection stage | Disease | Duration | Number of cells | Chimerism |
| Fleischman et al. | 1979 | [29] | W/W, Wv/Wv mouse | C57Bl/6, DBA/2 mouse | Fetal liver cell (E13–E15) | Hematopoiesis | Intraplacental | E11 | No | — | 1 × 105 | In peripheral blood is more in W/W than in Wv/Wv | Carrier et al. | 1995 | [30] | BALB/c, C57Bl/6 mouse | C57Bl/6 mouse | Fetal liver cell | Hematopoiesis | IP, intraplacental | E11–13 | No | 22–44 weeks | 5 × 105 | 10–62% (peripheral blood, liver, and spleen) | Archer et al. | 1997 | [74] | Nod/Scid, C57Bl/6 mouse | C57Bl/6-Ly-5.2 mouse | BM (lin-depleted) | Hematopoiesis | IP | E13.5 | No | PB analyzed 4 and 26 weeks | 8 × 105 | ~55% (peripheral blood, spleen, BM) | Kim et al. | 1999 | [75] | BALB/c mouse | DBA/2 mouse | BM | Hematopoiesis | IP | E14 | No | ~8 weeks | — | Successful skin grafts in 2 of 3 mice | Mackenzie et al. | 2002 | [66] | mdx C57Bl/10 mouse | Rosa26 mouse | BM, fetal liver cell | Multiple | IP | E14 | DMD | ~14 months | 5 × 106 BM, 1 × 106 fetal liver cell | Multiple tissues | Chou et al. | 2005 | [76] | BALB/c mouse | Human | MSC (BM) | Multiple | IP | E13-14 | No | ~5 months (postnatal) | 1 × 105 | ~56% in multiple tissues | Frattini et al. | 2005 | [77] | Oc+/−C57Bl/6 mouse | Mouse CD1 CMV-GFP | BM | Hematopoiesis | IP | E14.5 | Autosomal recessive osteopetrosis | ~7 months | 5 × 106 | Improved survival | Chan et al. | 2007 | [68] | MF1 and mdx C57Bl/10 mice | Human | MSC (fetal) | Muscle | IP, yolk sac vein, intramuscular | E14–16 | DMD | ~18 weeks (postnatal) | 5 × 103–1 × 106 | Multiple tissues | Li et al. | 2007 | [78] | oim/oim mouse | Mouse | MSC (BM) | Multiple | IP | — | No | — | — | Multiple tissues | Guillot et al. | 2008 | [79] | oim/oim mouse | Human | MSC (fetal) | Bone | IP | E13.5–15 | Osteogenesis imperfecta | E18, 1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks | — | Multiple tissues | Kun-Yi Lin et al. | 2013 | [80] | Mouse | Mouse | Amniotic fluid progenitor cells | Multiple | IP | E13.5 | No | 3, 6, and 9 weeks (postnatal) | — | Multiple tissues | Ihara et al. | 2015 | [81] | MPSVII mouse | ICR/B6 actin-GFP mouse | BM (lin-depleted) | Hematopoiesis | IV in vitelline vein | E14.5 | Mucopolysaccharidosis type VII | ~8 weeks (postnatal) | 5 × 105 | Multiple tissues | Cohen et al. | 2016 | [52] | Mouse (Wsh/Wsh) | Mouse, rat, and human | Mouse neural crest cell, mESC, riPSC, and hESC/hiPSC | Melanocyte | Intra-amniotic | E8.5 | No | E10.5–E18.5, postnatal | — | Skin pigmentation | Boelig et al. | 2016 | [31] | C57Bl/6TgN mouse | C57Bl/6 H-2K actin-GFP mouse | BM | Hematopoiesis | IV in vitelline vein, IP, intrahepatic | E14 | No | 4, 24, 72 hrs, and ~6 months (postnatal) | 5 × 106 IV, IP, intrahepatic, 2 × 107 IV | Multiple tissues | Munoz-Elias et al. | 2004 | [82] | Rat | Rat | MSC (BM) | Brain | Lateral ventricle | E15.5 | No | E17.5, E19.5, and E21.5; 3 days , 1 month, and 2 months (postnatal) | — | Neuronal tissues | Chen et al. | 2009 | [43] | Rat | Human | MSC (placental) | Multiple | IP | E17 | No | E21, 3 weeks, 12 weeks (postnatal) | — | ~60% in multiple tissues | Li et al. | 2012 | [83] | Wistar rat | Wistar rat | BM-MSC | Neurogenesis | Lumbosacral spine | E16–18 | Spina bifida aperta | E20 | 1–6 × 103 | Neuronal tissues | Munoz-Saez et al. | 2013 | [51] | Wistar rat | Wistar rat, Fischer | Fetal hepatocyte (E21) | Liver | IP | E17 | No | ~15 days (postnatal) | 1 × 106 | Multiple tissues | Li et al. | 2014 | [44] | Rat | Rat | MSC (BM) | Spinal cord | Spinal column | E16 | Spina bifida aperta | ~E20 | — | Spinal cord | Burai et al. | 2015 | [84] | Rat | Human | Amniotic cell | Multiple | — | E18 | No | 1, 4, 11, and 18 days | 2 × 105 | Multiple tissues | Touraine et al. | 1989 | [40] | Human | Human | Fetal liver, thymic epithelial cell | Hematopoiesis | Umbilical vein | 30 weeks | Bare lymphocyte syndrome | — | 1.6 × 107 | 10% in lymphocyte | Wengler et al. | 1996 | [37] | Human | Human | T cell-depleted CD34+ BM | Hematopoiesis | IP | 21 weeks | No | — | — | No GVHD, normal T cell response | Flake et al. | 1996 | [36] | Human | Paternal | BM (CD34+ paternal) | Hematopoiesis | IP | 16–18.5 weeks | — | At birth, 3 months, 6 months (postnatal) | 1.48–2 × 106 | All T cells | Gil et al. | 1999 | [38] | Human | Human | BM (paternal CD34+) | Hematopoiesis | IP | 23 weeks and 23 weeks + 10 days | SCID | — | 1.4 × 107, 6 × 106 | T cells | Westgren et al. | 2002 | [39] | Human | Human | Fetal liver cell (10 weeks) | Hematopoiesis | IP | 14 weeks | X-linked SCID | — | 7 × 107 | 10% (24 weeks), 50% (33 weeks), all T cells/NK cells are donor origin | Le Blanc et al. | 2005 | [46] | Human | Human | MSC (fetal liver) | Bone | Umbilical vein | 32 weeks | Osteogenesis imperfecta | — | 6.5 × 106 | Normal osteoblast distribution and trabeculae | Götherström et al. | 2014 | [85] | Human | Human | MSC (7-week, 3-day/10-week fetal liver) | Liver | Intrahepatic vein | 31 weeks | Osteogenesis imperfecta | 3–10 years (postnatal) | 4 × 107 | 7.4%, healed fractures | Harrison et al. | 1989 | [35] | Rh monkey | Rh Monkey | Fetal liver cell (days 59–68 opposite sex) | Hematopoiesis | IP | 60–62 days | No | ~2 years | 1 × 108–1 × 109/kg | Lymphoid, myeloid, and erythroid, no GVHD | Mychaliska et al. | 1997 | [34] | Monkey | Paternal | BM (T cell depleted) | Hematopoiesis | IP | 61 days | No | ~2 years | 1 × 108/kg | <0.1%, slower progression of rejection after kidney transplants | Shields et al. | 2003 | [86] | Baboon/cynomolgus monkey | Baboon monkey | BM (parental, T cell-depleted B), T cell | Hematopoiesis | IP | 0.34–0.38 gestation | No | ~2 years | 3 × 109 | Peripheral blood | Asano et al. | 2003 | [87] | Cynomolgus monkey | Cynomolgus monkey | ESC | Multiple | IP or intrahepatic | End of 1st trimester | No | 1, 3 months (posttransplantation) | 3.6–4.8 × 106 | Multiple tissues, small tumor | Crombleholme et al. | 1990 | [88] | Lamb | Sheep | BM (whole, T cell depleted) | Hematopoiesis | IP | — | No | — | — | 18% (whole), 6% (T cell depleted), No GVHD | Zanjani et al. | 1994 | [89] | Sheep | Human | CD45+ cell injected with human fetal HSC | Hematopoiesis | IP | 50–54 days | No | ~68 weeks (postnatal) | 4.9 × 106 | Chimerism found in 2 of 6 sheep | Almeida-porada et al. | 1999, 2000 | [90, 91] | Sheep | Human | BM + stromal cell | Hematopoiesis | IP | 55–60 days | No | 3, 6, and 9 weeks after transplantation; 3 days, 3 months, and 1–3 years (postnatal) | 5 × 104–7.5 × 105 | Peripheral blood | Liechty et al. | 2000 | [41] | Sheep | Human | MSC (BM) | Multiple | IP | 65 days, 85 days | No | 2 weeks, 2 months, 5 months, and 13 months | — | Multiple tissues | Mackenzie et al. | 2001 | [66] | Sheep | Human | MSC | Multiple | IP | 65 days, 85 days | No | — | 2 × 106 | Multiple tissues in 28 of 29 sheep | Emmert et al. | 2013 | [92] | Sheep | Human | MSC (adipose/BM) | Multiple | IP and intramyocardial | 70–75 days | No | 7–9 days (postnatal) | — | Multiple tissues | Jeanblanc et al. | 2014 | [93] | Sheep | Sheep/human (opposite sex) | BM (T cell depleted), BM (CD34+), and BM (human CD34+) | Hematopoiesis | IP | 45 days, 65 days | No | 10, 60, and 130 days and ~9 months (posttransplantation) | 5 × 105 BM, 1.4 × 106 CD34+, and 4 × 104–5 × 105 human CD34+ | In blood cells at day 65 |
|
|